Compare CSW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | NAMS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | Netherlands |
| Employees | 2600 | 100 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | CSW | NAMS |
|---|---|---|
| Price | $284.87 | $34.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $321.40 | $46.75 |
| AVG Volume (30 Days) | 120.7K | ★ 811.1K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.19 | $17.96 |
| Revenue Next Year | $18.95 | $540.65 |
| P/E Ratio | $40.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $230.45 | $15.82 |
| 52 Week High | $337.02 | $42.00 |
| Indicator | CSW | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 55.01 |
| Support Level | $284.40 | $29.73 |
| Resistance Level | $333.30 | $37.43 |
| Average True Range (ATR) | 11.55 | 1.77 |
| MACD | 4.79 | 0.38 |
| Stochastic Oscillator | 56.87 | 64.34 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.